Johnson & Johnson Completes Acquisition of Halda Therapeutics and Its ...

Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Dec 29, 2025-

Johnson & Johnson acquires Halda Therapeutics for $3.05bn

Johnson & Johnson (J&J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for $3.05bn in cash.

J&J completes $3.05B Halda Therapeutics acquisition

Johnson & Johnson finalized its $3.05 billion acquisition of clinical-stage biotech Halda Therapeutics OpCo. Inc. In a Dec. 29 press release announcing the closing, the New Brunswick-based pharmaceutical giant said the move will expand its presence in solid tumors and prostate cancer treatments. New Haven-headquartered Halda was founded in 2019. The company developed a proprietary modality that employs a novel “hold and kill” mechanism for the p…

JNJ stock edges higher after Johnson & Johnson closes $3.05B Halda deal; earnings outlook next

NEW YORK, December 29, 2025, 14:38 ET — Regular session Johnson & Johnson shares were up about 0.3% at $208.28 in afternoon trading on Monday after the healthcare conglomerate said it had completed its $3.05 billion cash acquisition of Halda Therapeutics. JNJ.com The close matters because it brings Johnson & Johnson a clinical-stage oncology platform and assets as investors press large drugmakers to keep replenishing their pipelines ahead of pat…

Johnson & Johnson completes $3.05B acquisition of Halda Therapeutics to redefine cancer treatment

New Brunswick-based Johnson & Johnson announced the successful completion of its $3.05 billion acquisition of Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer. With this acquisition, Johnson & Johnson adds HLD-0915, a clinical-stage therapy for pr…

Johnson & Johnson completes acquisition of Halda Therapeutics and its ...